Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats

Neuroendocrinology Letters

Volumn 28, Issue 5, 2007, Pages 614-620

  Dronjak, Sladjana ^a   Spasojevic, Natasa ^a   Gavrilovic, Ljubica ^a   Varagic, Vladislav ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Faculty of Medicine   (Serbia)

Author keywords

ACTH; Antidepressant; Catecholamines; Chronic mild unpredictable stress; CORT

Indexed keywords

ADRENALIN; CORTICOSTERONE; CORTICOTROPIN; FLUXILAN; MAPROTILINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADRENAL MEDULLA; ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DRUG MECHANISM; EXPERIMENTAL TEST; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; RAT;

EID: 38049010913     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Blardi P, Lalla A, Auteri A, Iapichino S, Dell'Erba, Castrogiovanni P. (2005). Plasma catecholamine levels after fluoxetine treatment in depressive patients. Neuropsychobiol. 51: 72-76.
2. Brady LS, Whitfield HJ, Fox R, Gold PW, Herkenham M. (1991). Long term antidepressive administration alters corticotropin-releasing hormone, tyrosine hydroxylase and mineralocorticoid gene expression in the rat. J Clin invest. 87: 831-837.
3. Chaouloff F (2000). Serotonin, stress and corticoids. J Psychopharmacol. 14: 139-151.
4. Dazzi S, Ladu S, Spiga F, Vacca G, Rivano A, Pira L, Biggio G. (2002). Chronic treatment with imipramine or mitrazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats. Synapse 43: 70-77.
5. Dazzi S, Seu E, Cherchi G, Biggo G. (2005). Chronic administration of the SSRI fluvoxamine markedly and selectively reduces the sensitivity of cortical serotonergic neurons to footshock stress. Eur Neuropsychopharmacol. 15: 283-290.
6. Durand M, Berton O, Agueree S, Edno L, Combourie I, Mormede P, Chaoulloff F. (1999). Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic system, and the corticotropic axis in SHR and WKY rats. Neuropharmacol. 38: 893-907.
7. Fujii S, Asakura M, Kanai S, Tanaka D, Hishinumai T, Nagashima H. (2004). Effect of concurrent treatment of SSRI on the tyrosine hydroxylase immunoreactivity in the rat locus coeruleus treated with chronic variable stress. Nihon Shin Seis Yakur Zasshi. 24: 21-27.
8. Gavrilovic L and Dronjak S. (2005). Activation of rat pituitara-adrenocortical and sympatho-adrenomedullary system in response to different stressors. Neuroendocrinol Lett. 26: 481-486.
9. Gobert A, Rivet JM, Cistarelli L, Millan MJ. (1997). Buspirone enhances duloxetine- and fluoxetine-incluced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem. 69: 2616-2619.
10. Grippo AJ, Moffitt JA and Johnson AK (2002). Cardiovascular alterations and autonomic imbalance in an experimental model of depression. Am J Physiol Regul integr Comp Physiol. 282: 1333-1341.
11. Grippo AJ, Beltz TG, Weiss RM, Johnson AK. (2006). The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiat. 59: 309-316.
12. Holsboer F and Barden V (1996). Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrinol Rev. 17: 187-205.
13. Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR. (2001). Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacol. 156: 73-78.
14. Jensen I, Llewellyn-Smith IJ, Pilowsky P, Minson JB, Chalmers J. (1995). Serotonin inputs to rabbit sympathetic preganglionic neurons projecting to the superior cervical ganglion or adrenal medulla. J Copm Neurol. 353: 427-38.
15. Jezova D and Duncko R (2002). Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men. J Psychopharm. 16: 235-240.
16. Jongsma ME, Bosker FJ, Cremers TI, Westerink Bh, den Boer JA. (2005). The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin(1B) receptor sensitivity and HPA axis activity. Prog Neuropsychopharmacol Biol Psychat. 29: 738-744.
17. Kelliher P, Kelly JP, Leonard BE, Sanchez C. (2003). Effects of acute and chronic administration of selective monoamine re-uptake inhibitors in the rat forced swim test. Psychoneuroendocrinol. 28: 332-347.
18. Korte SM, Van Duin S, Bouws GA, Koolhaas JM, Bohus B. (1991). Involvement of hypothalamic serotonin in activation of the sympatho-adrenomedullary system and hypothalamo-pituitary-adrenocortical axis in male Wistar rats. Eur J Pharmacol. 197: 225-228.
19. 3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures. Eur J Pharmacol. 256: 269-279.
20. Montgomery SA (1995). Selective serotonin reuptake inhibitors in the acute treatment of depression. In:. Bloom FE and Kupfer DJ, editors. Psychopharmacology The Fourth Generation of Progress. New York: Raven Press. p. 15-19
21. Montgomery SA (1997). Is there a role for a pure noradrenergic drug in the treatment of depression?. Eur Neuropsychopharmacol. 7: 3-9.
22. Page ME and Abercrombie ED (1997). An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress. Neuropsychopharmacol. 16: 419-425.
23. Pariante CM and Miller AII (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiat. 49: 391-404.
24. Peuler JD and Johnson GA (1977). Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci. 21, 625-636.
25. Reul JM, Stec I, Soder M, Holsboer F. (1993). Chronic treatment of rat with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinol. 133: 312-320.
26. Shachar D, Klein E, Tabak A, Finberg JR (1997). Effect of single and repeated administration of fluvoxamine on noradrenaline release in rat brain. Eur J Pharmacol. 332: 237-243.
27. Stanford SC (1996). Stress: a major variable in the psychopharmacologic response. Pharmacol Biochem Behav. 54: 211-217.
28. Szabo ST, de Montigny C and Blier P (1999). Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol. 126: 568-571.
29. Torpy DJ, Grice JE, Hockings GI, Crosbie GV, Walters MM, Jackson RV. (1995). The effect of desipramine on basal and naloxone-stimulated secretion in humans: interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion. J Clin Endocrinol Metab. 80: 802-806.
30. Willner R Muscat R and Papp M (1992). Chronic mild stress-induced anhedonia. A realistic animal model of depression. Neurosci Biobehav Rev. 16: 525-534.
31. Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression. A 10-year review and evaluation. Psychopharmacol. 134: 319-329.
32. Xia X, Pan Y, Zhang WY, Cheng G, Kong LD. (2006). Ethanolic extract from Curcuma longa attenuates behavioral, immune, and neuroendocrine alterations in a rat chronic mild stress model. Biol Pharm Bull. 29: 938-944.